February 27, 2020 / 9:09 AM / a month ago

BRIEF-GSK Says EMA Accepted Submission Of Co's Marketing Authorisation Application For Zejula (Niraparib)

Feb 27 (Reuters) - GlaxoSmithKline PLC:

* EUROPEAN MEDICINES AGENCY ACCEPTS SUBMISSION OF GSK’S MARKETING AUTHORISATION APPLICATION FOR ZEJULA (NIRAPARIB) IN FIRST-LINE MAINTENANCE TREATMENT FOR WOMEN WITH PLATINUM-RESPONSIVE ADVANCED OVARIAN CANCER

* SUBMISSION BASED ON DATA FROM PRIMA STUDY, DEMONSTRATED CLINICALLY MEANINGFUL OUTCOMES OF NIRAPARIB TREATMENT IN FIRST-LINE MAINTENANCE SETTING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below